Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren, Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren

Abstract

Background: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL.

Methods: This was an open-label, two-stage, phase 2 study that enrolled 57 patients aged ≥ 18 years with classic HL that had progressed after standard therapy. Patients received everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision. The primary endpoint was overall response rate; secondary endpoints included PFS, overall survival, time to response, duration of response, and safety.

Results: Overall response rate was 45.6% (95% confidence interval [CI] 32.4-59.3%); five patients (8.8%) experienced a complete response and 21 patients had a partial response (36.8%). Median PFS was 8.0 months (95% CI 5.1-11.0 months). Seven patients (12%) were long-term responders (≥ 12 months). The most common study drug-related adverse events were thrombocytopenia (45.6%), fatigue (31.6%), anemia (26.3%), rash (24.6%), and stomatitis (22.8%).

Conclusions: Everolimus 10 mg/day demonstrated favorable results in patients with heavily pretreated, relapsed, or refractory classical HL. These findings support the further evaluation of everolimus in this indication.Trial registration ClinicalTrials.gov NCT01022996. Registered November 25, 2009.

Keywords: Clinical trial; Everolimus; Hodgkin lymphoma; Relapsed/refractory; mTOR inhibitors.

Figures

Fig. 1
Fig. 1
Kaplan–Meier estimate of progression-free survival
Fig. 2
Fig. 2
Kaplan–Meier estimate of overall survival

References

    1. National Cancer Institute. Cancer stat facts: Hodgkin lymphoma. 2013. . Accessed 13 Jan 2017.
    1. National Cancer Institute. SEER cancer statistics review, 1975–2010. . Updated 14 June 2013. Accessed 13 Jan 2017.
    1. National Comprehensive Cancer Network. Hodgkin Lymphoma (Version 3.2018). . Accessed 9 May 2018.
    1. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208–4217. doi: 10.1182/blood-2010-09-288373.
    1. Eichenauer DA, Engert A, Dreyling M, ESMO Guidelines Working Group Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl 6):vi55–vi58.
    1. Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist. 2012;17:367–376. doi: 10.1634/theoncologist.2011-0258.
    1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054. doi: 10.1016/0140-6736(93)92411-L.
    1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–2071. doi: 10.1016/S0140-6736(02)08938-9.
    1. Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R, et al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32:279–285. doi: 10.1038/sj.bmt.1704110.
    1. Currin ESR, Gopal AK. Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol. 2012;47:8–16. doi: 10.5045/kjh.2012.47.1.8.
    1. Ruiz-Arguelles GJ, Lopez-Martinez B, Lopez-Ariza B. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin’s disease following autologous stem cell transplantation. Arch Med Res. 2003;34:242–245. doi: 10.1016/S0188-4409(03)00005-5.
    1. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–1821. doi: 10.1056/NEJMoa1002965.
    1. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189. doi: 10.1200/JCO.2011.38.0410.
    1. Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10:34. doi: 10.1186/s13045-017-0403-5.
    1. Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10:174. doi: 10.1186/s13045-017-0541-9.
    1. Bristol-Myers Squibb Company . OPDIVO (nivolumab) injection, for intravenous use. Princeton: Bristol-Myers Squibb Company; 2017.
    1. Merck Sharp & Dohme Corp . KEYTRUDA® (pembrolizumab) for injection, for intravenous use. County Cork: Merck Sharpe & Dohme, Corp; 2017.
    1. Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W, Feldman RA. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin’s lymphoma-derived cell line (CO) Leukemia. 2002;16(894–901):19.
    1. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005;205:498–506. doi: 10.1002/path.1725.
    1. Nagel S, Scherr M, Quentmeier H, Kaufmann M, Zaborski M, Drexler HG, MacLeod RAF. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3 K signalling involving E2F3. Leukemia. 2005;19:841–846. doi: 10.1038/sj.leu.2403716.
    1. De J, Brown RE. Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with non-Hodgkin’s lymphoma. Int J Clin Exp Med. 2010;3:55–68.
    1. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165–5173. doi: 10.1158/1078-0432.CCR-06-0764.
    1. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1408–1414. doi: 10.1200/JCO.2009.24.0994.
    1. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106:1801–1807. doi: 10.1182/blood-2004-11-4513.
    1. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(320–4):26.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.
    1. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin. 2007;21:841–854. doi: 10.1016/j.hoc.2007.06.011.
    1. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236–1243. doi: 10.1182/blood-2014-08-595801.
    1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. doi: 10.1200/JCO.2013.54.8800.
    1. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47:1287–1298. doi: 10.1016/j.ejca.2011.02.014.
    1. Yardley DA. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer. 2014;14:297–308. doi: 10.1016/j.clbc.2014.03.002.
    1. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014;28:126–133. doi: 10.1016/j.trre.2014.03.002.
    1. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197–2203. doi: 10.1200/JCO.2011.38.1350.
    1. Rueda A, Garcia-Sanz R, Pastor M, Salar A, Labrador J, Quero-Blanco C, et al. A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. Acta Oncol. 2015;54(933–8):35.
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319. doi: 10.1056/NEJMoa1411087.
    1. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024–4031. doi: 10.1182/blood-2014-12-614636.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren